drugset
Drugs / Allogeneic CD5.CAR/28zeta CAR T cells
last change Nov 2017 re-read 3 minutes ago

Allogeneic CD5.CAR/28zeta CAR T cells

Cell therapy

Developed for
T-cell acute lymphoblastic leukemia · T-lymphoblastic lymphoma
Investigated by
Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · National Cancer Institute (NCI) · The Methodist Hospital Research Institute

Trials 1

today NCT03081910 · Ph 1
20182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03081910 Nov 2017 → Jun 2028 expected T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma Baylor College of Medicine Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic CD5.CAR/28zeta CAR T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03081910 ↗
Modality Cell therapy “Allogeneic CD5.CAR/28zeta CAR T cells” NCT03081910 ↗
Route Intravenous “The patient will be given an injection of CD5.CD28 Chimeric Receptor T cells into the vein through an IV at the assigned dose.” NCT03081910 ↗